ArticleAnnals of hematology2026
Favorable outcome in TCF3::HLF-positive pediatric B-cell acute lymphoblastic leukemia without classic metabolic complications: A case report.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The t(17;19)(q22;p13) translocation, generating the TCF3::HLF fusion oncogene, occurs in < 1% of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and is associated with extreme chemotherapy resistance, frequent metabolic complications including hypercalcemia and disseminated intravascular coagulation (DIC), both of which have been reported with variable frequencies across published cohorts depending on the underlying TCF3::HLF fusion subtype, together with an extremely poor long-term prognosis. A 3-year-old girl with TCF3::HLF-positive BCP-ALL presented with fever, lethargy, and pancytopenia, but notably lacked hypercalcemia and overt disseminated intravascular coagulation (DIC). Cytogenetic analysis additionally revealed a high hyperdiploid karyotype (52-58 chromosomes) and duplication of 1q. She was treated with a high-risk Children's Oncology Group (COG) protocol (prednisone, vincristine, daunorubicin, PEG-asparaginase), achieving a day-8 blast count < 1000/µL and complete remission with an exceptionally low flow-cytometric MRD of less than 0.01%. She underwent myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) from a matched related donor and remains in complete remission(CR) more than 2 years post-transplantation. This case suggests that TCF3::HLF-positive ALL encompasses a clinical spectrum rather than a uniformly fatal disease. The absence of classic metabolic complications and the co-occurrence of high hyperdiploidy might delineate a subgroup with a better response to intensive chemotherapy and early HSCT. Larger studies integrating detailed molecular characterization are required to substantiate this hypothesis and guide risk-adapted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.